299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03485456 (ClinicalTrials.gov)	May 29, 2019	26/3/2018	DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis	Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic Fibrosis	Cystic Fibrosis	Drug: Tobramycin	University Medical Center Groningen	NULL	Recruiting	6 Years	18 Years	All	10	Phase 1/Phase 2	Netherlands
2	NCT03341741 (ClinicalTrials.gov)	March 11, 2014	3/11/2017	Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients	Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients	Cystic Fibrosis With Pulmonary Manifestations	Drug: Tobramycin Powder;Drug: Colistin	University Hospital Tuebingen	NULL	Completed	12 Years	N/A	All	26	Phase 3	NULL
3	NCT02035488 (ClinicalTrials.gov)	October 2013	27/12/2013	Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis	Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis	Bronchiectasis	Drug: Tobramycin	University Medical Centre Groningen	NULL	Completed	18 Years	N/A	Both	8	Phase 1/Phase 2	Netherlands
4	EUCTR2012-004437-16-NL (EUCTR)	15/05/2013	19/03/2013	Pharmacokinetic evaluation and local tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis	Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis - Tobra-02	BronchiectasisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Dry powder tobramycin Product Code: J01GB01 INN or Proposed INN: Tobramycin dry powder Other descriptive name: TOBRAMYCIN	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
5	EUCTR2016-005014-21-NL (EUCTR)		31/10/2020	Pharmacokinetic evaluation and tolerability of dry powder tobramycin viathe Cyclops® in children with cystic fibrosis	Pharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis - DPI-tobra-child	Cystic FibrosisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Dry powder tobramycin Product Code: J01GB01 INN or Proposed INN: TOBRAMYCIN Other descriptive name: TOBRAMYCIN Product Name: Nebulization tobramycin INN or Proposed INN: TOBRAMYCIN Other descriptive name: TOBRAMYCIN	University Medical Center Groningen	NULL	NA			Female: yes Male: yes	10	Phase 2	Netherlands